Blueprint Medicines (BPMC) News Today

Blueprint Medicines Co. (NASDAQ:BPMC - Free Report) - Investment analysts at Leerink Partnrs dropped their Q2 2024 earnings per share estimates for shares of Blueprint Medicines in a research report issued to clients and investors on Wednesday, July 24th. Leerink Partnrs analyst A. Berens now for

Vanguard Group Inc. raised its stake in shares of Blueprint Medicines Co. (NASDAQ:BPMC - Free Report) by 3.2% in the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 6,309,977 shares of the biotechnology company's stock after buyin

Blueprint Medicines (NASDAQ:BPMC) will be releasing earnings before the market opens on Thursday, August 1, Zacks reports. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=610152)

Russell Investments Group Ltd. lifted its stake in Blueprint Medicines Co. (NASDAQ:BPMC - Free Report) by 44.3% during the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 57,714 shares of the biotechnology company's stock after buyi

SG Americas Securities LLC lifted its stake in Blueprint Medicines Co. (NASDAQ:BPMC - Free Report) by 117.6% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 11,865 shares of the biotechnology company's stock after bu

Susquehanna Fundamental Investments LLC bought a new position in shares of Blueprint Medicines Co. (NASDAQ:BPMC - Free Report) during the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm bought 5,000 shares of the biotechn

Shares of Blueprint Medicines Co. (NASDAQ:BPMC - Get Free Report) have been assigned a consensus rating of "Moderate Buy" from the sixteen brokerages that are presently covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, five have a

Morgan Stanley upped their price target on Blueprint Medicines from $110.00 to $115.00 and gave the stock an "equal weight" rating in a research note on Friday.

Blueprint Medicines (NASDAQ:BPMC) Sets New 1-Year High at $119.82

Blueprint Medicines Co. (NASDAQ:BPMC - Get Free Report) insider Debra Durso-Bumpus sold 3,850 shares of the company's stock in a transaction that occurred on Friday, July 5th. The stock was sold at an average price of $111.20, for a total transaction of $428,120.00. Following the completion of the sale, the insider now directly owns 43,763 shares of the company's stock, valued at approximately $4,866,445.60. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website.

Blueprint Medicines (NASDAQ:BPMC) Trading 5.1% Higher on Analyst Upgrade

Blueprint Medicines (NASDAQ:BPMC) Reaches New 12-Month High at $111.99

Principal Financial Group Inc. lifted its position in shares of Blueprint Medicines Co. (NASDAQ:BPMC - Free Report) by 331.9% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 62,670 shares of the biotechnology c

Blueprint Medicines Co. (NASDAQ:BPMC - Get Free Report) insider Debra Durso-Bumpus sold 333 shares of the stock in a transaction on Friday, June 28th. The shares were sold at an average price of $111.15, for a total value of $37,012.95. Following the transaction, the insider now directly owns 43,763 shares of the company's stock, valued at $4,864,257.45. The sale was disclosed in a document filed with the SEC, which is accessible through this link.

Blueprint Medicines Co. (NASDAQ:BPMC - Get Free Report) was the recipient of unusually large options trading activity on Friday. Investors bought 3,146 call options on the stock. This represents an increase of 557% compared to the typical daily volume of 479 call options.

Blueprint Medicines (NASDAQ:BPMC) Reaches New 1-Year High at $111.42

Blueprint Medicines Co. (NASDAQ:BPMC - Get Free Report) insider Debra Durso-Bumpus sold 74,034 shares of the stock in a transaction dated Friday, June 21st. The shares were sold at an average price of $104.19, for a total transaction of $7,713,602.46. Following the completion of the transaction, the insider now directly owns 43,763 shares in the company, valued at $4,559,666.97. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Blueprint Medicines (NASDAQ:BPMC) Trading 3.1% Higher

Vanguard Group Inc. increased its holdings in Blueprint Medicines Co. (NASDAQ:BPMC - Free Report) by 2.5% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 6,114,970 shares of the biotechnology company's sto

Fisher Asset Management LLC trimmed its position in shares of Blueprint Medicines Co. (NASDAQ:BPMC - Free Report) by 14.5% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 326,664

Granahan Investment Management LLC decreased its position in Blueprint Medicines Co. (NASDAQ:BPMC - Free Report) by 26.9% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 167,507 shares of the biotechnology

Avidity Partners Management LP lessened its stake in Blueprint Medicines Co. (NASDAQ:BPMC - Free Report) by 18.2% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 615,000 shares of the biotechnology company's stock after selling 136,600 shares during the quarter.

Sectoral Asset Management Inc. reduced its holdings in shares of Blueprint Medicines Co. (NASDAQ:BPMC - Free Report) by 98.5% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 2,470 shares of the biotechnology comp

Blueprint Medicines Co. (NASDAQ:BPMC - Get Free Report) insider Percy H. Carter sold 4,000 shares of the firm's stock in a transaction that occurred on Wednesday, June 5th. The stock was sold at an average price of $105.13, for a total transaction of $420,520.00. Following the sale, the insider now directly owns 41,895 shares in the company, valued at approximately $4,404,421.35. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

JMP Securities reiterated a "market outperform" rating and issued a $125.00 target price on shares of Blueprint Medicines in a report on Friday.

Rafferty Asset Management LLC decreased its position in Blueprint Medicines Co. (NASDAQ:BPMC - Free Report) by 27.2% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 121,368 shares of the biotechnology company's stock a

Eagle Asset Management Inc. raised its position in shares of Blueprint Medicines Co. (NASDAQ:BPMC - Free Report) by 10.7% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 231,396 shares of the biotechnolog

Axiom Investors LLC DE acquired a new position in Blueprint Medicines Co. (NASDAQ:BPMC - Free Report) in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 23,982 shares of the biotechnology company's stock

Norges Bank purchased a new position in Blueprint Medicines Co. (NASDAQ:BPMC - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 605,951 shares of the biotechnology com

Shares of Blueprint Medicines Co. (NASDAQ:BPMC - Get Free Report) have received a consensus rating of "Moderate Buy" from the seventeen research firms that are presently covering the firm, Marketbeat Ratings reports. Two equities research analysts have rated the stock with a sell recommendation, fi

Trexquant Investment LP acquired a new position in shares of Blueprint Medicines Co. (NASDAQ:BPMC - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm acquired 56,932 shares of the biotechnology company's

Brown Advisory Inc. lifted its stake in Blueprint Medicines Co. (NASDAQ:BPMC - Free Report) by 6.1% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 679,920 shares of the biotechnology company's stock after buying

Blueprint Medicines Co. (NASDAQ:BPMC - Get Free Report) was the recipient of a large increase in short interest in the month of April. As of April 30th, there was short interest totalling 4,540,000 shares, an increase of 6.8% from the April 15th total of 4,250,000 shares. Based on an average daily volume of 830,500 shares, the short-interest ratio is presently 5.5 days.

Blueprint Medicines Co. (NASDAQ:BPMC - Free Report) - Analysts at Zacks Research issued their Q2 2024 earnings per share estimates for shares of Blueprint Medicines in a note issued to investors on Tuesday, May 14th. Zacks Research analyst A. Chakraborty anticipates that the biotechnology company